BIOSIMILARS.com
Biosimilars, Follow-on Biologics and Proteins, Subsequent Entry Biologics, Similar Biological Medicinal Products, BioBetters, Biogenerics, Generic Biopharmaceuticals, etc.

The Biosimilars Information Resource for the Biopharmaceutical Industry

Coming: The most comprehensive biosimilars and biobetters pipeline reference!   Information about well over 425 candidate biosimilars and 350 biobetters in the development pipeline, from preclinical through marketed, plus the over 350 companies involved. US and EU patent and market and data exclusivity expirations have been calculated for over 100 candidate currently-approved reference products (and through these, US and EU biosimilar and biobetter launchable dates are provided).  Some top-level data are shown in the figures below and in this presentation.  To receive a publication announcement, please provide your E-mail address.

Product Entries by Class (n = 911)
biosimilars = 427; biobetters = 367; ref. products = 117
pipeline products (biosimilars + biobetters) = 788
Note, this study covers protein protducts, now nearly all recombinant proteins. Vaccines, blood-derived, cellular, cultured tissues and other types of biologics are not included!


Note, "2011" indicates marketable before or in 2011.

    "N.A." columin on right refers to pipeline products for which the reference product cannot be determined (e.g., which of several interferon alfa-2 reference products a biosimilar seeks to emulate).


The number of companies in different regions. Products can have multiple companies involved.

    The total number of products associated with companies in different regions.

    Top Companies In Terms of Products*
    Roche/Genentech 35
    Harvest Moon Pharmaceuticals USA, Inc. 29
    Novo Nordisk A/S 25
    Novartis AG 25
    Pfizer Inc. 20
    BioXpress Therapeutics S.A. 18
    Biogen Idec 18
    Lilly, Eli & Co. 18
    Merck KGaA 17
    Merck & Co., Inc. 16
    Biocon Ltd. 14
    Inbiopro Solutions Pvt Ltd. 14
    Green Cross Corp. 14
    Baxter 14
    Bio Sidus S.A. 13
    LG Life Sciences Ltd. 13
    Bioton S.A. 13
    Sanofi S.A. 12
    Bayer AG 12
    Dong-A Pharmaceutical 12
    Bolder BioTechnology, Inc. 12
    Amega Biotech 11
    AXXO GmbH 11
    Teva Pharmaceutical Industries Ltd. 11
    Chemo Group (Grupo Insud ) 11
*Companies involved with the most products, i.e., product entries; 4/23/2012). The total number of product entries, including biosimilars, biobetters and reference products, indexed to these companies. Note, this list and this report does not include the specific products from many of the likely future leaders in biosimilars/biobetters, with most of these companies, including the largest (bio)pharmaceutical and generic drug companies, not yet disclosing their plans or products in the pipeline. Many or most of these and other companies will be licensing in products presented in this study.
    This list is a mixture of big international companies (currently, primarily involved with established reference products and biobetters) and those 'biosimilar' companies claiming the broadest pipelines.

Biosimilars.com 

Related articles by the Webmaster:

Need a Consultant With Biosimilars Expertise? - The Web master, Ronald A. Rader, is available.  See his short bio and full resume. Mr. Rader is the author of BIOPHARMA, the only information resource/reference specializing in biopharmaceuticals (see www.biopharma.com), has authored the defining articles concerning biopharmaceuticals and biosimilars/FOBs (e.g., see the "What is...", "(Re)Defining" and related abstracts/links above), and is a world-class expert concerning biopharmaceutical information, products, techologies, and related market, technology and policy assessments. 
Sponsors needed!   Without financing and/or collaboration with a view towards the long term, we (Biotech. Info. Inst.) do not foresee commercial viability for our solely developing biosimilar information resources. There simply are too few involved with too few opportunities for cost-recovery, much less profit; and there are no plans to devalue this site by taking advertising. Thus, corporate or other funding or collaboration is needed. We envision developing the best (or only) Web site/database/reference providing substantive authoritive, including (bio)technical, information about biosimilars (and biobetters and biogenerics). To learn more, contact Ron Rader.